1. Japan Stocks

  2. •

    Technology

  3. •

    Semiconductors
Rorze Corporation

Rorze Corporation

6323.T
Rorze CorporationJP flagTokyo Stock Exchange
4,548.00
JPY
+204.00
- -
788.77BMarket Cap
Rorze Corporation
6323.T
(Tokyo Stock Exchange)

Recent

price

4,548.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
65.46
61.3
55.65
83.45
73.86
115.4
143.15
302.34
181.51
214.7
293.98
387.73
546.94
529.25
705.78
739.26
638.66
Revenue per Share
3.66
0.78
-0.84
2.38
5.02
12.51
17.68
15.87
25.45
31.66
37.44
74.21
123.74
111.11
134.08
109.33
145.3
Basic EPS, GAAP
-1.03
4.56
3.87
1.61
4.21
4.32
14.68
-11.17
-34.76
3.34
33.05
5.21
-37.57
80.84
196.25
153.38
- -
Free Cash Flow per Basic Share
- -
0.2
0.3
0.3
0.5
0.5
1.5
2.3
2
2.5
3
3
6.5
13.24
13.49
17.21
- -
Dividend per Share
41.39
41.94
40.77
42.46
46.27
58.23
68.73
87.79
111.06
140.22
174.66
245.86
359.94
450.93
571.31
670.15
527.57
Book Value per Share
43.64
43.39
47.22
58.86
65.48
76.51
92.55
119.21
137.15
162.03
197.1
287.05
429.07
535.37
658.7
750.45
623.98
Tangible Book Value per Share
168
168
168
170
173
173
173
173
173
173
173
173
173
176
176
174
176
Basic Weighted Avg Shares
10,990
10,301
9,359
14,167
12,751
19,943
24,739
52,249
31,368
37,103
50,803
67,004
94,518
93,247
124,406
128,794
112,484
Sales/Revenue/Turnover
10.55
4.62
6.06
8.2
6.13
14.74
18.48
8.11
18.53
20.87
18.33
23.6
27.95
25.89
25.74
24.19
27.85
Operating Margin (%)
377
455
385
375
407
388
390
509
610
961
1,290
1,521
1,980
2,804
4,537
6,246
- -
Depreciation Expense
614
131
-142
404
866
2,162
3,055
2,743
4,398
5,471
6,470
12,824
21,384
19,576
23,634
19,048
25,591
Net Income, GAAP
25.73
49.17
130.4
40.43
20.58
26.27
27.46
24.91
25.26
26.53
22.6
25.22
25.22
25.78
28.93
30.07
22.71
Effective Tax Rate (%)
5.59
1.28
-1.51
2.85
6.79
10.84
12.35
5.25
14.02
14.74
12.74
19.14
22.62
20.99
19
14.79
22.75
Profit Margin (%)
3,614
3,842
4,637
5,897
6,689
8,632
9,960
15,054
18,890
18,577
21,088
37,964
66,942
83,710
104,856
114,642
96,588
Working Capital
1,995
1,861
1,997
1,809
1,426
1,345
568
2,660
7,943
7,809
5,299
8,961
17,887
18,174
16,660
8,216
17,739
LT Debt
7,566
7,498
8,146
10,194
11,550
13,463
16,231
20,847
23,941
28,571
34,606
50,220
74,792
99,546
128,715
139,959
124,211
Total Equity
6.68
1.87
-1.32
4.85
3.95
12.44
16.7
12.82
12.29
12.69
14.38
18.44
21.07
14.29
14.9
12.98
16.22
Return on Invested Capital (%)
3.91
0.2
-1.41
1.55
7.43
13.71
16.83
11.77
13.65
12.9
12.64
19.95
23.7
17.17
18.31
14.13
19.48
Return on Capital (%)
9.24
1.88
-2.04
5.74
11.4
23.95
27.85
20.28
25.6
25.2
23.78
35.29
40.85
27.64
26.24
17.52
31.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
ST Debt
16,339
15,363
19,411
LT Borrowings
18,167
16,846
17,739
LT Finance Leases
7
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
176
176
176
Market Capitalization
370,652
532,781
392,409

Working Capital

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
Total Current Assets
120,140
123,589
137,292
Cash, Cash Equivalents & STI
37,951
40,206
55,080
Accounts Receivable, Net
26,456
27,870
26,953
Inventories
53,284
53,396
53,122
Total Current Liabilities
36,430
34,664
40,704
Payables & Accruals
- -
- -
- -
ST Debt
16,339
15,363
19,411
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.95%
33.04%
8.74%
Free Cash Flow
-4.91%
-220.96%
-22.75%
Net Income, GAAP
29.19%
31.57%
-19.4%
Sales/Revenue/Turnover
25.9%
21.71%
3.53%
Total Cash Common Dividend
53.77%
50.48%
26.07%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,693
24,299
24,170
28,085
93,247
2025
29,288
30,941
- -
- -
124,406
2026
- -
- -
- -
- -
128,794

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.19
- -
- -
- -
111.11
2025
49.82
- -
- -
- -
134.08
2026
- -
- -
- -
- -
109.33

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
13.24
2025
- -
- -
- -
- -
13.49
2026
- -
- -
- -
- -
17.21
Similar Companies
TE Connectivity plc (TEL)
Guangdong Real-Design Intelligent Technology Co., Ltd (301135.SZ)
RN2 Technologies Co., Ltd. (148250.KQ)
Taiwan Semiconductor Manufacturing Company Limited (2330.TW)
WISeKey International Holding AG (0RF1.L)
POET Technologies Inc. (POETF)
Business
Rorze Corporation engages in the development, design, manufacture and sale of automation systems for semiconductor and flat panel display production, as well as life science automation products; its core offerings include wafer handling systems such as atmospheric robots, vacuum wafer robots, aligners, load ports, vacuum platforms, EFEMs/sorters and stockers; mask/reticle handling systems; system integration and package services; control devices including controllers, stepping motors and drivers; FPD-related products like extra-large substrate transfer systems, in-line returnable transfer systems, cell type extra-large packing equipment, display module equipment and laser cutting equipment; and life science products comprising CO2 incubators with medium exchange and cell imaging functions such as CellKeeper II 48Plus, automatic medium exchange systems like CellFarm(L)-360, scheduling software Green Button Go, incubators SCALE48 and mobile robots. The company operates globally with manufacturing facilities in Japan, sales and support in key markets including China, the US, Taiwan, Korea, Europe, Singapore and Vietnam, and subsidiaries such as RORZE AUTOMATION Inc in the US, RORZE ROBOTECH Co Ltd in Vietnam, RORZE SYSTEMS CORPORATION in Korea and RORZE CREATECH CO LTD in China. Founded in 1985 and headquartered in Fukuyama-shi, Hiroshima, Japan, Rorze lists on the Tokyo Stock Exchange Prime Market under ticker 6323. Recent developments include making Nanoverse Technologies Ltd a 33%-owned consolidated subsidiary through a $70 million investment in 2024 to develop advanced packaging semiconductor equipment using its EFEM products; acquiring Genostaff Co Ltd as a subsidiary of RORZE Lifescience Inc in September 2024 for tissue staining, gene analysis and related instruments; and commencing operations of affiliate Preciv Co Ltd in Vietnam in December 2024 for precision machine parts manufacturing.